Achilles Therapeutics Plc - ADR

ACHL | $0.7827 -2.16% -2.21% 200K

(0.0% 1d) (-37.8% 1m) (-8.8% 1y) (0.0% 2d) (0.0% 3d) (-2.5% 7d) (-48.21% volume)
Earnings Calendar:
Market Cap: $ 31,213,392
https://www.achillestx.com
Sec Filling | Patents | n/a employees

(United Kingdom) Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

ceiling cancer lung cancer lungs t-cell

add to watch list Paper trade email alert is off

Press-releases

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -31.44% | O: -16.22% H: 0.99% C: -7.89%
business therapeutics financial results

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -31.44% | O: -16.22% H: 0.99% C: -7.89%
first melanoma update therapeutics advanced

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Published: 2024-02-05 (Crawled : 12:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -18.48% | O: -3.46% H: 14.74% C: 3.16%
conference therapeutics

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -5.66% | O: 0.98% H: 1.09% C: -0.52%
cancer publication therapeutics

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| 0.28% | O: 3.74% H: 1.19% C: -2.4%
therapeutics financial results

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Published: 2023-09-22 (Crawled : 21:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| Email alert Add to watchlist
nasdaq therapeutics

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Published: 2023-09-20 (Crawled : 16:00) - biospace.com/
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -7.16% | O: 0.9% H: 5.52% C: 2.96%
JAZZ | $109.96 0.63% 0.63% 760K

Health Technology

| -18.77% | O: 0.58% H: 1.04% C: 0.84%
GNPX | $2.2194 -2.31% 38K

Health Technology

| 388.4% | O: -0.55% H: 3.29% C: -0.44%
ALXO M | $15.6 -0.89% -0.9% 480K

Commercial Services

| 192.14% | O: -0.2% H: 1.21% C: -2.63%
drug biotech designation

Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Published: 2023-08-04 (Crawled : 11:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -19.38% | O: 0.5% H: 1.0% C: -0.5%
business therapeutics financial results

Achilles Therapeutics to Present at Upcoming Conferences
Published: 2023-06-12 (Crawled : 12:00) - globenewswire.com
ACHL | $0.7827 -2.16% -2.21% 200K

Manufacturing

| -17.3% | O: 0.52% H: 4.07% C: -2.46%
therapeutics